Payment overview · 2025
General Payments
$793.39
41 reported records · 17 companies
Healthcare provider profile · identity verified
Eva Leigh Bartlett, MD
Allopathic & Osteopathic Physicians|Family Medicine · SHERIDAN, MI · NPI 1912044215
Verified facts
What the public records show
CMS Open Payments records show Eva Leigh Bartlett, MD received $793.39 in general payments during 2025 across 41 reported records.
ABBVIE INC. accounted for 19.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $150.50 | 19.0% | 8 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $100.22 | 12.6% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.19 | 9.7% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $61.85 | 7.8% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $52.37 | 6.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.30 | 6.0% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $44.07 | 5.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.80 | 5.3% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $33.57 | 4.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.74 | 4.0% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.97 | 3.6% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $28.21 | 3.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $26.34 | 3.3% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $18.36 | 2.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.00 | 2.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.91 | 2.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.99 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $793.39 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $100.22 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $87.44 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $77.19 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $52.37 | 2 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $44.86 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $44.07 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $41.80 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $33.57 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $31.74 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $31.25 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.12 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.12 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $28.97 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $28.21 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $26.34 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| Kyleena Normalized: kyleena |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| Mirena Normalized: mirena |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 52 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 550 | 151 |
| Lisinopril | Lisinopril | 408 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 320 | 84 |
| Omeprazole | Omeprazole | 307 | 81 |
| Metformin Hcl | Metformin Hcl | 222 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 167 | 58 |
| Losartan Potassium | Losartan Potassium | 154 | 40 |
| Gabapentin | Gabapentin | 149 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 148 | 35 |
| Trazodone Hcl | Trazodone Hcl | 145 | 35 |
| Amlodipine Besylate | Amlodipine Besylate | 137 | 47 |
| Montelukast Sodium | Montelukast Sodium | 136 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 135 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 133 | 33 |
| Simvastatin | Simvastatin | 131 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 119 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 46 |
| Furosemide | Furosemide | 114 | 37 |
| Prednisone | Prednisone | 113 | 72 |
| Tizanidine Hcl | Tizanidine Hcl | 109 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 107 | 32 |
| Famotidine | Famotidine | 104 | 29 |
| Meloxicam | Meloxicam | 102 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 27 |
| Potassium Chloride | Potassium Chloride | 96 | 30 |
| Carvedilol | Carvedilol | 93 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 92 | 24 |
| Bupropion Xl | Bupropion Hcl | 90 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 87 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 85 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 84 | 27 |
| Topiramate | Topiramate | 84 | 20 |
| Atenolol | Atenolol | 82 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 82 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 82 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 19 |
| Ozempic | Semaglutide | 73 | 15 |
| Eliquis | Apixaban | 72 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 72 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 67 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 65 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 17 |
| Metformin Hcl Er | Metformin Hcl | 60 | 18 |
| Tramadol Hcl | Tramadol Hcl | 58 | suppressed |
| Lamotrigine | Lamotrigine | 55 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 20 |
| Januvia | Sitagliptin Phosphate | 54 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 14 |
| Jardiance | Empagliflozin | 52 | 16 |
| Sertraline Hcl | Sertraline Hcl | 52 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 13 |
| Alendronate Sodium | Alendronate Sodium | 49 | 15 |
| Xarelto | Rivaroxaban | 49 | 12 |
| Allopurinol | Allopurinol | 48 | 11 |
| Baclofen | Baclofen | 47 | 17 |
| Ibuprofen | Ibuprofen | 47 | 16 |
| Cephalexin | Cephalexin | 46 | 37 |
| Ventolin Hfa | Albuterol Sulfate | 46 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 15 |
| Buspirone Hcl | Buspirone Hcl | 44 | 19 |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Amoxicillin | Amoxicillin | 42 | 28 |
| Finasteride | Finasteride | 42 | 13 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 40 | suppressed |
| Azithromycin | Azithromycin | 39 | 33 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 39 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | 11 |
| Ezetimibe | Ezetimibe | 36 | suppressed |
| Spironolactone | Spironolactone | 36 | suppressed |
| Risperidone | Risperidone | 35 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Methocarbamol | Methocarbamol | 32 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 30 |
| Naproxen | Naproxen | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 11 |
| Trulicity | Dulaglutide | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 19 |
| Ipratropium Bromide | Ipratropium Bromide | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 20 |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 12 |
| Diazepam | Diazepam | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 20 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | 11 |
| Mirtazapine | Mirtazapine | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 16 |
| Dilt-Xr | Diltiazem Hcl | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Nystatin | Nystatin | 18 | 12 |
| Ondansetron Odt | Ondansetron | 18 | 14 |
| Cefdinir | Cefdinir | 17 | 12 |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Buprenorphine | Buprenorphine | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Glyburide | Glyburide | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Xtampza Er | Oxycodone Myristate | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Metaxalone | Metaxalone | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $793.39 · 41 records | ABBVIE INC. | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, Dexcom G6 Transmitter, EVENITY, FANAPT, FARXIGA, JARDIANCE, Kyleena, MAVYRET, Mirena, OTEZLA, QULIPTA, Qelbree, REPATHA, REXULTI, SUBLOCADE, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, Wegovy, XYOSTED, YUPELRI | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error